P135 SPIRIT: Switching to rilpivirine/emtricitabine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48 regardless of viral load or CD4 + count prior to initiation of ARV therapy
E Wilkins¹, M Fisher², F Palella³, P Tebas⁴, B Gazzard⁵, P Ruane⁶, J Van Lunzen⁷, D Shamblaw⁸, J Flamm⁹, R Ebrahimi¹⁰, K White¹⁰, W Guyer¹⁰, D Porter¹⁰, A Smith¹¹ and T Fralich^10
1North Manchester General Hospital, Manchester, UK, ²Brighton and Sussex University Hospital, Brighton, UK, ³Northwestern University, Chicago, USA, ⁴University of Pennsylvania, Philadelphia, USA, ⁵Chelsea and Westminster Hospital, London, UK, ⁶Peter J Ruane MD Inc, Los Angeles, USA, ⁷ID Unit University Medical Centre, Hamburg, Germany, ⁸La Playa Medical Group, San Diego, USA, ⁹Kaiser Permanente, Sacramento, USA, ¹⁰Gilead Sciences, Foster City, USA and ¹¹Gilead Sciences, Cambridge, UK

P136 STaR Study: Single tablet regimen rilpivirine/emtricitabine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adults regardless of baseline viral load and CD4 + count
E Wilkins¹, C Cohen², D Wohl³, J Arribas⁴, K Henry⁵, J Van Lunzen⁶, M Bloch⁷, W Towner⁸, H Wang⁹, D Porter⁹, S De-Oertel⁹, K Aizen¹⁰ and T Fralich^9
1North Manchester General Hospital, Manchester, UK, ²Community Research Initiative of New England, Boston, USA, ³University of North Carolina at Chapel Hill, North Carolina, USA, ⁴Hospital La Paz, Madrid, Spain, ⁵HIV Program Hennepin County Medical Center, Minneapolis, USA, ⁶Infectious Disease Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁷Holdsworth House Medical Practice, Sydney, Australia, ⁸Kaiser Los Angeles Medical Center, Los Angeles, USA, ⁹Gilead Sciences, Foster City, USA and ¹⁰Gilead Sciences, Cambridge, UK

P137 Efficacy and Safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF from an integrated analysis of Phase 2 and 3 clinical trials
M Fisher¹, D Ward², G Crowfoot³, D Shamblaw⁴, N Bellos⁵, S Chen⁶, M Rhee⁶, K Aizen⁷ and J Szwarcberg^6
1Brighton and Sussex University Hospital, Brighton, UK, ²Du Pont Circle Physicians Group, Washington DC, USA, ³G Crowfoot, Houston, USA, ⁴La Playa Medical Group, San Diego, USA, ⁵South West Infectious Disease Inc, Dallas, USA, ⁶Gilead Sciences, Foster City, USA and ⁷ Gilead Sciences, Cambridge, UK

P138 Patient and physician preferences regarding medications for HIV treatment
A Lloyd¹, D Collomb², S Hearn¹, S Ali¹ and F Mughal^3
1Oxford Outcomes, Oxford, UK, ²AstraZeneca, Luton, UK and ³AbbVie Ltd, Maidenhead, UK

P139 Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naïve HIV-1-infected patients
C Orkin¹, J Rockstroh², E DeJesus³, K Henry⁴, J Molina⁵, J Gathe⁶, X Wei⁷, M Fordyce⁷, M Rhee⁷, A Smith⁸ and J Szwarcberg^7
1St Bartholomew's Hospital, London, UK, ²University of Bonn, Bonn, Germany, ³Orlando Immunology Center, Orlando, USA, ⁴Hennepin County Medical Center, Minneapolis, USA, ⁵St Louis Hospital, Paris, France, ⁶Therapeutic Concepts P. A., Houston, USA, ⁷Gilead Sciences, Foster City, USA and ⁸Gilead Sciences, Cambridge, UK

P140 Nevirapine use in a large multi-ethnic South London HIV cohort
R Brum¹, E Mabonga¹, R Rajani², C Taylor¹ and E Cheserem^1
1King's College Hospital, London, UK and ²Guy's and St Thomas' Hospital, London, U.K.

P141 Switching to rilpivirine in clinical practice: experience of two London HIV units
N Marshall¹, L Hedley², L Swaden¹, C Smith³, N Brima², R Tsintas¹, P Benn², M Tyrer¹, L Waters², S Edwards² and M Johnson^1
1Royal Free London NHS Foundation Trust, London, UK, ²Mortimer Market Centre, NHS Camden Provider Services, London, UK and ³University College London, London, UK

P142 Use of antacid preparations with HAART
T Constandinou¹, S Vekeria², GKJ Singh², M Bower² and M Nelson^2
1Imperial College School of Medicine, London, UK and ²Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

P143 Abstract withdrawn

P144 HLA B*5701 positivity, disease status and response to combination antiretroviral therapy (cART) in the UK Collaborative HIV Cohort (CHIC) study
S Jose¹, C Sabin¹, C Leen² and D Chadwick³, for the UK CHIC Study
¹University College London, London, UK, ²University of Edinburgh, Edinburgh, UK and ³James Cook University Hospital, Middlesbrough, UK

P145 Long-term therapeutic success of etravirine in switch and naïve patients
L Bull, M Bower and M Nelson
Chelsea and Westminster Hospital, London, UK

P146 Real-life clinical experience with Eviplera™
A Gothard, E Wilkins and A Ustianowski
Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK

P147 Rilpivirine in clinical practice
H Alexander¹, K Seneviratne², Y Kamuntu¹, C Richardson², Y Gilleece², A de Ruiter¹ and A Teague^1
1Guy's and St Thomas' NHS Trust, London, UK and ²Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

P148 Safety and efficacy of rilpivirine-tenofovir-emtricitabine in treatment-experienced patients infected with HIV-1
M Cevik¹, L Guy², S Sonecha¹ and M Nelson^1
1Chelsea and Westminster Hospital, London, UK and ²Imperial College Hospital, London, UK

P149 Five years of experience with raltegravir in a large HIV centre
C van Halsema¹, T Whitfield¹, N Lin², K Millington¹, A Thompson¹, A Gothard¹ and A Ustianowski^1
1North Manchester General Hospital, Manchester, UK and ²Manchester Medical School, Manchester, UK

P150 Treatment change within 12 months of starting highly active antiretroviral therapy (HAART) in HIV-positive therapy-naïve patients
M McNulty, J Leighton, L McFarlane and A Ustianowski
North Manchester General Hospital, Manchester, UK

P151 The use of dual maraviroc/ritonavir-boosted darunavir combination in clinical practice
V Vishwanath¹, GKJ Singh², S Dub¹, M Bower² and M Nelson^2
1Imperial College School of Medicine, London, UK and ²Chelsea and Westminster Hospital, London, UK

P152 Newly licensed darunavir suspension: clinical experiences
C Okoli, K Khonyongwa, J Ainsworth, A Schwenk and C Wood
North Middlesex University Hospital NHS Trust, London, UK

P153 Salvage therapy with protease inhibitor-sparing regimens containing etravirine
L Bull, M Bower and M Nelson
Chelsea and Westminster Hospital, London, UK

P154 Re-audit: Late presentation of HIV-positive patients in a small city in the UK
N Dean, S Cherif and K Yoganathan
Singleton Hospital, Abertawe Bro Morgannwg University Health Board, Swansea, UK

P155 Dual antiretroviral therapy in a treatment-experienced HIV cohort
H Wiggins¹, N Ahmed², P Benn², S Edwards² and L Waters^2
1Watford General Hospital, Watford, UK and ²Mortimer Market Centre, London, UK

P156 Eviplera® 1 year on: experience of a large teaching hospital
M Phillips, C Saxon, B McBrien and G Schembri
Central Manchester NHS Foundation Trust, Manchester, UK

P157 Indications for changing to raltegravir therapy in patients with a pre-existing undetectable viral load
V Van-de-Velde, M Nelson, M Bower and S Sonecha
Chelsea and Westminster Hospital, London, UK

P158 Systematic review of existing evidence on the costs and cost-effectiveness of interventions to enhance uptake and adherence to antiretroviral therapy
IP Molosankwe¹, S Byford¹, P McCrone¹ and R Horne^2
1King's College London, London, UK and ²University College London, London, UK

P159 Antiretroviral absorption after biliopancreatic diversionduodenal switch: a case report
J Beale and S Andrews
Farnham Road Clinic, Guildford, UK

P160 Zidovudine: going, going, gone?
L Johnson, A Teasdale, N Sithamparanathan, P Hine and E Wilkins
North Manchester General Hospital, Manchester, UK

P161 Clinical audit: Initiation of antiretroviral treatment regimen in a small city HIV clinic during 2011 and 2012
S Cherif, C Williams, S Danino and K Yoganathan
Singleton Hospital, Abertawe Bro Morgannwg University Health Board, Swansea, UK

P162 Clinical outcomes after switching HIV-positive patients with HIV viral load less than 100 copies from a PI-based regimen to a tenofovir, emtricitabine and efavirenz regimen
V Sivaraj¹, B Connolly¹, M-Y Tung² and P Key^1
1Darent Valley Hospital, Dartford, UK and ²Kent Community Health NHS Trust, Canterbury, UK

P163 Early experience of rilpivirine use in a medium-sized HIV cohort
R Taylor, A Darley and A Jayasuriya
Nottingham University Hospitals NHS Trust, Nottingham, UK